Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)

NCT06031181 · tracked via the Priya Life Science China tracker

Sponsor

Fudan University

Phase

Phase 3

Started

2023-03-31

Last updated

2023-12-13

Condition(s) studied

Lung AdenocarcinomaFrozen SectionSublobar Resection

Investigational drug(s) / intervention(s)

Sublobar Resection

Sublobar Resection: Sublobar Resection includes segmentectomy and wedge resection

Study summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1019. The goal of this clinical trial is to confirm the therapeutic effect of sublobar resection for AIS/MIA diagnosed by intraoperative frozen section.

Eligibility

Sex

ALL

Min age

18 Years

Max age

80 Years

Healthy volunteers

Inclusion Criteria: 1. Patients who sign the informed consent form and are willing to complete the study according to the plan; 2. Aged from 18 to 80 years old; 3. ECOG equals 0 or 1; 4. Not receiving lung cancer surgery before; 5. Resectable peripheral cT1N0M0 tumors; 6. Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiple lung nodules with the major lesion being the aforementioned nodules; 7. Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section 8. Not receiving chemotherapy or radiotherapy before. Exclusion Criteria: 1. Not cT1N0M0; 2. Cannot be completely resected by sublobar resection; 3. Invasive lung adenocarcinoma or not lung adenocarcinoma diagnosed cytologically or pathologically; 4. Receiving lung cancer surgery before; 5. Receiving radiotherapy or chemotherapy.

Primary outcome measure(s)

5-year recurrence-free survival — 5 years
The event is defined as the tumor recurrence.

Trial sites (1)

Facility	City	Region	Status
Fudan University Cancer Center	Shanghai	Shanghai Municipality	Recruiting

More Fudan University trials in China

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases Recruiting

Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment Recruiting

Selective Neck Dissection Versus Modified Neck Dissection in PTC Recruiting

MRI-Driven Precision Typing and Response Prediction in Luminal Breast Cancer Active, not recruiting

Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma Recruiting

Other trials for the same condition

Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers Recruiting

Lymph Node Pathologic Grading Strategy Recruiting

Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm Recruiting

Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung Adenocarcinoma Enrolling by invitation

Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06031181 on ClinicalTrials.gov ↗ ← All trials in China